Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this Phase IIa study is to evaluate the safety, tolerability and
pharmacodynamics of ALLN-346 in subjects with hyperuricemia and gout, and with mild to
moderate chronic kidney disease.